Michael Makris: Romiplostim Use Allows More Chemotherapy to Be Delivered on Time
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared a post on LinkedIn about a recent article by Hanny Al-Samkari et al, published in The New England Journal of Medicine:
“Romiplostim use allows more chemotherapy to be delivered on time.
A paper in this week’s New England Journal of Medicine by Hanny Al-Samkari and colleagues reports on a double-blind study of Romiplostim vs Placebo for Chemotherapy-induced Thrombocytopenia.
84% of the Romiplostim and 36% of the Placebo group had no chemotherapy dose modifications.
All the patients had solid tumours.
We do not know if administering more chemo results in a survival advantage, since this would have required a larger trial and much longer follow-up.”
Title: Romiplostim versus Placebo for Chemotherapy-Induced Thrombocytopenia
Authors: Hanny Al‑Samkari, César Muñoz, Çağlayan Geredeli, Ippokratis Korantzis, Beatriz González Astorga, Cagatay Arslan, Johnny Francisco Cordeiro Camargo, Florian Scotté, Giuliano Borges, Kejia Wang, Melissa Eisen, David J. Kuter, Gerald A. Soff
Read the Full Article on The New England Journal of Medicine

Other articles featuring Michael Makris on Hemostasis Today.
-
Jun 15, 2026, 13:51Miguel Gómez Álvarez: Navigating the Complexities of Erythrocytosis and the Role of PIEZO1
-
Jun 15, 2026, 13:37Katja Sockel: EHA 2026 Inspires New Ideas and Global Connections
-
Jun 15, 2026, 13:25Srishti Goyal։ India’s Blood Donation Journey – Looking Beyond the Numbers
-
Jun 15, 2026, 13:22Debra BenAvram: Every Two Seconds – Someone Needs Blood
-
Jun 15, 2026, 13:13Christina Ornauer: Exploring the Latest Advances in Hematology at EHA 2026
-
Jun 15, 2026, 13:05Angelo Zanniti: Back from EHA 2026 Congress
-
Jun 15, 2026, 12:56Chiara Pirillo: Building Global Connections at EHA 2026
-
Jun 15, 2026, 12:50Marina Planas: MRD and Molecular Monitoring Take Center Stage at EHA 2026
-
Jun 15, 2026, 12:46Moonmoon Kazi: Climb Bio Presents Phase 1b ITP Trial Data at EHA 2026